High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?

Romain Ragonnet, James M. Trauer, Justin T. Denholm, Ben J. Marais and Emma S. McBryde

Globally 3.9% of new and 21% of re-treatment tuberculosis (TB) cases are multidrug-resistant or rifampicin-resistant (MDR/RR), which is often interpreted as evidence that drug resistance results mainly from poor treatment adherence. This study aims to assess the respective contributions of the different causal pathways leading to MDR/RR-TB at re-treatment.

January 18, 2017
Year of publication
2016
Resource types
Journal and research articles
Tags
re-treatment, TB, tuberculosis, rifampicin-resistant TB (RR-TB), multidrug-resistant TB (MDR-TB), multidrug-resistant or rifampicin-resistant (MDR/RR), drug resistance, treatment

Similar Resources

Although the number of deaths worldwide from tuberculosis—a disease caused by the bacterium Mycobacterium tuberculosis—fell by 22% between 2000 and 2015, it remains humanity’s biggest infectious killer and one of the top ten causes of all deaths.

Tuberculosis disproportionately affects hard-to-reach populations, such as homeless people, migrants, refugees, prisoners, or drug users. These people often face challenges in accessing quality health care.

Fungi are major contributors to the opportunistic infections that affect patients with HIV/AIDS.

The Southern African HIV Clinicians Society’s biannual conference, held in Johannesburg, South Africa, from 24-27 October 2018, focused on clinical content for HIV and TB health care workers in the region and featured a wide range of topics…

Adolescents newly diagnosed with HIV need to be rapidly incorporated into HIV care networks to have the best chances of remaining in care in the long term, research from the United States published in the June 1st edition of the Journal of Acquired Immune Deficiency Syndromes shows.

BACKGROUND:

Attrition along the HIV care continuum slows gains in mitigating the South African HIV epidemic. Understanding population-level gaps in HIV identification, linkage, retention in care and viral suppression is critical to target programming.

There is significant attrition at each stage of the HIV care continuum in South Africa, according to a study published in the online edition of the Journal of Acquired Immune Deficiency Syndromes. The population-based research was conducted in North West Province and revealed that of…

High adherence to antiretroviral therapy is crucial to the success of HIV treatment. We evaluated comparative effectiveness of adherence interventions with the aim of informing the WHO's global guidance on interventions to increase adherence.

Despite more than two decades of research on adherence to antiretroviral therapy (ART) and more than 17 million HIV-positive individuals on treatment, adherence to ART remains a major challenge. This review aimed to assess the most frequently reported barriers to adherence by patients…